| Discipline | Toxicology andpharmacology |
|---|---|
| Language | English |
| Edited by |
|
| Publication details | |
| History | 1981–present |
| Publisher | Elsevier on behalf of the International Society of Toxicology & Pharmacology |
| Frequency | Monthly |
| 3.271 (2021) | |
| Standard abbreviations ISO 4 (alt) · Bluebook (alt) NLM (alt) · MathSciNet (alt  ) | |
| ISO 4 | Regul. Toxicol. Pharmacol. |
| Indexing CODEN (alt · alt2) · JSTOR (alt) · LCCN (alt) MIAR · NLM (alt) · Scopus · W&L | |
| CODEN | RTOPDW |
| ISSN | 0273-2300 |
| LCCN | 81646304 |
| OCLC no. | 485750423 |
| Links | |
Regulatory Toxicology and Pharmacology is a monthlypeer-reviewedscientific journal which covers legal aspects oftoxicological and pharmacological regulations. It is published byElsevier on behalf of the International Society of Regulatory Toxicology & Pharmacology. The current co-editors-in-chief are Lesa L. Aylward and Martin van den Berg.
In 2002, a group of 45 academics wrote a letter accusing the journal of a concealed pro-industry bias, a possible lack of full and independent peer review, and a failure to discloseconflicts of interest, citing a case in whichGio Batta Gori, then-currenteditor-in-chief, was paid $30,000 by theTobacco Institute to write an article later published in the journal dismissing the health risks ofsecondhand smoke.[1][2] The letter's coordinator later commented that the journal "reads like an industry trade publication, but it's masked as a peer-reviewed journal" and that it lacked any "credible peer-review process."[3] In response, the journal's publisher implemented a conflict of interest disclosure policy at the journal in January 2003, shortly before the correspondence was published.[1]
An analysis of 52 articles published in the journal abouttobacco ornicotine between January 2013 and June 2015 identified that among 50 of them at least one of the authors had ties withtobacco industry. In 38 of those 50 papers, the conclusions were positive for the industry while none was negative. The two papers without any ties to the industry had conclusions negative towards the industry. The authors of the article question the confidence the scientific community can have in the journal.[4]
The journal is abstracted and indexed inEMBASE,EMBiology, andScopus.
According to theJournal Citation Reports, the journal has a 2014impact factor of 2.031, ranking it 56th out of 87 journals in the category "Toxicology"[5] and 146th out of 254 journals in the category "Pharmacology & pharmacy".[6]